Browse by author
Lookup NU author(s): Emeritus Professor David Brooks, Professor Nicola PaveseORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© The Author(s) 2024.The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.
Author(s): Sauerbier A, Herberg J, Stopic V, Loehrer PA, Ashkan K, Rizos A, Jost ST, Petry-Schmelzer JN, Gronostay A, Schneider C, Visser-Vandewalle V, Evans J, Nimsky C, Fink GR, Antonini A, Martinez-Martin P, Silverdale M, Weintraub D, Schrag A, Ray Chaudhuri K, Timmermann L, Dafsari HS, Adler C, Bhidayasiri R, Borghammer P, Barone P, Brooks DJ, Brown R, Cantillon M, Carroll C, Coelho M, Falup-Pecurariu C, Henriksen T, Hu M, Jenner P, Jeon B, Kramberger M, Kumar P, Kurtis M, Leta V, Lewis S, Litvan I, Lyons K, Martino D, Masellis M, Mochizuki H, Morley JF, Nirenberg M, Odin P, Pagonabarraga J, Panicker J, Pavese N, Pekkonen E, Postuma R, Rodriguez Violante M, Rosales R, Schapira A, Simuni T, Stocchi F, Storch A, Subramanian I, Tagliati M, Tinazzi M, Toledo J, Tsuboi Y, Walker R
Publication type: Article
Publication status: Published
Journal: npj Parkinson's Disease
Year: 2024
Volume: 10
Issue: 1
Online publication date: 08/06/2024
Acceptance date: 02/04/2024
Date deposited: 26/06/2024
ISSN (electronic): 2373-8057
Publisher: Nature Research
URL: https://doi.org/10.1038/s41531-024-00701-6
DOI: 10.1038/s41531-024-00701-6
Data Access Statement: The data used to support the findings of this study are available from the corresponding author upon reasonable request (specification of a clear research question and preparedness to enter legal data-sharing agreements).
Altmetrics provided by Altmetric
